公开(公告)号：US20170233339A1

公开(公告)日：2017-08-17

申请号：US15518782

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Takahiko TANIGUCHI ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D207/08

CPC classification number: C07D207/08 ,  A61K31/40 ,  A61K31/401 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20210269420A1

公开(公告)日：2021-09-02

申请号：US17256330

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko FUJIMOTO ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Kentaro RIKIMARU ,  Yoshihiro BANNO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Yoshihide TOMATA ,  Yuji ISHICHI ,  Shogo MARUI ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE

IPC: C07D401/14 ,  C07D405/14 ,  C07D211/56

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20240390508A1

公开(公告)日：2024-11-28

申请号：US18685457

申请日：2022-08-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takatoshi YOGO ,  Hideyuki SUGIYAMA ,  Kenichi MIYATA ,  Hiroyuki TAKADA ,  Masato YOSHIDA ,  Ryosuke TOKUNOH ,  Yasuo NAKAGAWA ,  Masato NIWA ,  Shigekazu SASAKI ,  Masaki OHUCHI ,  Naoki SAWAI ,  Masatoshi TAKUWA ,  Yujiro UCHINO ,  Yoko KANEMATSU ,  Koichiro FUKUDA ,  Takanori YOKOTO ,  Tetsuya NAGATA ,  Hiroki YAMADA

IPC: A61K47/64 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

Abstract: The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

公开(公告)号：US20230042358A1

公开(公告)日：2023-02-09

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Jun CHIBA ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D455/02 ,  A61P25/26 ,  C07D471/04 ,  C07D217/24 ,  C07D239/90 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D498/04 ,  C07D417/06 ,  C07D401/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220081399A1

公开(公告)日：2022-03-17

申请号：US17154712

申请日：2021-01-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko FUJIMOTO ,  Kentaro RIKIMARU ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Mariko HIROZANE

IPC: C07D211/24 ,  C07D215/44 ,  C07D211/36 ,  C07D211/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US20190031611A1

公开(公告)日：2019-01-31

申请号：US16075240

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko FUJIMOTO ,  Kentaro RIKIMARU ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Mariko HIROZANE

IPC: C07D211/36 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US20240174610A1

公开(公告)日：2024-05-30

申请号：US18347345

申请日：2023-07-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko FUJIMOTO ,  Kentaro RIKIMARU ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Mariko HIROZANE

IPC: C07D211/24 ,  A61P25/00 ,  C07D211/36 ,  C07D211/56 ,  C07D215/44 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

CPC classification number: C07D211/24 ,  A61P25/00 ,  C07D211/36 ,  C07D211/56 ,  C07D215/44 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):






wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US20220017514A1

公开(公告)日：2022-01-20

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D471/04 ,  C07D231/56 ,  C07D277/64 ,  C07D215/38 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20190263843A1

公开(公告)日：2019-08-29

申请号：US16410463

申请日：2019-05-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro RIKIMARU ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Mariko HIROZANE

IPC: C07F7/18 ,  C07D405/06 ,  C07D417/06 ,  C07D413/06 ,  C07D409/12 ,  C07D409/06 ,  C07D405/14 ,  C07D211/24 ,  C07D417/14 ,  C07D401/14 ,  C07D401/12 ,  C07D401/06 ,  C07D211/56 ,  C07D405/12

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US20180237404A1

公开(公告)日：2018-08-23

申请号：US15517227

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D263/46 ,  C07D213/70 ,  C07D231/12 ,  A61P27/02

CPC classification number: C07D263/46 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/505 ,  A61P27/02 ,  C07D213/65 ,  C07D213/70 ,  C07D231/12 ,  C07D231/22 ,  C07D239/34 ,  C07D263/38 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.